3D In Vitro Alveolar Lung Model for Human Toxicity Assessment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for assessing the safety and biological responses of inhaled substances in humans rely heavily on animal models, which are costly, time-consuming, and provide inaccurate representations of human lung physiology, lacking a regulatory standard for in vitro inhaled safety assessment and failing to accurately represent the complex nature of the alveolar region.
Innovation Solution
A three-dimensional in vitro alveolar lung model is developed, comprising a culture well with a membrane separating two compartments, where alveolar type I epithelial cells are in one compartment and alveolar macrophage-like cells are in the other, allowing for exposure to an air-liquid interface or submerged conditions, enabling the assessment of inhaled products' toxicity and biological responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If animal models are used for inhaled safety assessment, then comprehensive biological responses can be studied, but the models are costly, time-consuming and do not provide accurate representation of human lungs
Solution Approach 1:
The patent creates an in vitro human lung model that copies the structure and function of human alveolar tissue using human-derived cell lines. This includes forming an alveolar epithelium layer with type I and type II pneumocytes, incorporating pulmonary capillary endothelium, and adding interstitial cells, thereby creating a human-specific model that eliminates the need for animal studies while maintaining physiological relevance.
Solution Approach 2:
The patent segments the complex lung tissue into distinct functional compartments: an alveolar epithelium compartment with type I and type II pneumocytes, a capillary endothelium compartment, and an interstitial compartment. This segmentation allows each cell type to be cultured and studied separately while maintaining their native interactions, enabling comprehensive safety assessment without using animal models.
2Productivity
If simple in vitro cell culture models are used, then assessment is faster and cheaper, but they only involve one cell type and are not representative of the complex nature of the lung
Solution Approach 1:
The patent merges multiple human cell lines representing different lung tissue compartments into a single integrated in vitro model. This includes combining alveolar epithelial cells (type I and type II pneumocytes), pulmonary capillary endothelial cells, and interstitial cells (fibroblasts and immune cells) to create a multi-cellular system that maintains the complex interactions found in native lung tissue while enabling efficient in vitro assessment.
Solution Approach 2:
The patent creates a composite tissue model using multiple human cell lines that together replicate the complexity of lung tissue. The model comprises alveolar type I pneumocytes (90-95% of alveolar surface), type II pneumocytes, capillary endothelium, and interstitial cells, forming a composite structure that accurately represents human lung physiology for safety assessment.
3Ease of manufacture
If A549 alveolar type II epithelial cells are used, then cell culture is easier, but they cannot form tight junctions and the model cannot be used to study permeation of substances
Solution Approach 1:
The patent changes the cell type parameter from A549 type II pneumocytes to primary human alveolar type I pneumocytes or type I/II co-cultures. Type I pneumocytes are capable of forming tight junctions and maintaining epithelial barrier function, which enables the study of substance permeation and transport across the alveolar epithelium while maintaining physiological relevance.
4Device complexity
If THP-1 monocyte derived macrophages are used, then co-culture is simpler, but they represent blood-derived monocytes and are not representative of alveolar macrophage lineage
Solution Approach 1:
The patent changes the macrophage cell line parameter from THP-1 (blood-derived) to primary human alveolar macrophages or U937 cells differentiated to resemble alveolar macrophages. This parameter change ensures the immune component of the model accurately represents the alveolar macrophage lineage, which is critical for studying inhaled substance toxicity and immune responses in the lung.
Data Source
AI summary
The invention relates to a human in vitro model and a method of constructing the same to mimic the alveolar region of the airways to assess the respiratory toxicology and/or physiological and/or biological response of inhaled products, chemicals and particles. There is provided a three-dimensional in vitro alveolar lung model and a method of constructing the same comprising a culture well provided with a membrane configured to separate the culture well into a first compartment and a second compartment, wherein the membrane has first side configured form a wall of the first compartment and a second side configured to form a wall of the second compartment, wherein alveolar type I epithelial cells are provided in the first compartment and alveolar macrophage-like cells are provided in the second compartment.